Last updated: January 30, 2026
Summary
Cinacalcet Hydrochloride, marketed primarily as Sensipar by Amgen, is a calcimimetic agent approved for secondary hyperparathyroidism in chronic kidney disease (CKD) patients on dialysis and for parathyroid carcinoma hypercalcemia. This report provides a comprehensive update on ongoing and recent clinical trials, analyzes current market dynamics, and projects future growth trajectories through 2030. Factors influencing its market include clinical advancements, evolving treatment guidelines, regulatory interventions, and competitive landscape shifts.
Clinical Trials Overview
Current and Recent Clinical Trials
| Trial ID |
Phase |
Status |
Objective |
Target Indication |
Sponsor |
Completion Date |
Key Outcomes |
| NCT02239013 |
Phase 4 |
Completed (2020) |
Long-term Safety & Efficacy |
Secondary Hyperparathyroidism |
Amgen |
- |
Confirmed sustained PTH control with acceptable safety profile, no new safety signals |
| NCT03112937 |
Phase 3 |
Recruiting |
Evaluation of Cinacalcet in CKD Patients not on Dialysis |
CKD without dialysis |
NIDDK |
Estimated Dec 2024 |
Assessing PTH, calcium, phosphate levels; safety in earlier-stage CKD |
| NCT04471123 |
Phase 2 |
Ongoing |
Cinacalcet for Hypercalcemia in Parathyroid Carcinoma |
Parathyroid carcinoma |
NCI |
Estimated Jun 2023 |
Investigates efficacy and safety; preliminary data favorable |
| NCT04873294 |
Phase 3 |
Recruiting |
Combination Therapy with Vitamin D Analogues |
Secondary hyperparathyroidism |
Amgen |
Expected Dec 2025 |
Aims to optimize dosing strategies |
Recent Findings
- Safety Profile: Long-term data reinforce Cinacalcet's tolerability (NCT02239013). Common adverse effects include nausea, hypocalcemia, and vomiting.
- Expanded Indications: Trials targeting non-dialysis CKD populations (NCT03112937) seek to broaden therapeutic scope.
- New Formulations: Investigational usage of oral formulations with improved bioavailability and reduced side effects.
Regulatory Updates:
In July 2022, the FDA approved a liquid oral solution formulation for easier administration in pediatric cohorts and for elderly patients with swallowing difficulties.
Market Analysis
Existing Market Landscape
| Parameter |
Details |
| Market Size (2022) |
USD 380 million (global) |
| Key Players |
Amgen (Sensipar), specialized biotech companies developing calcimimetics, generic manufacturers |
| Major Indications |
Secondary hyperparathyroidism in CKD, parathyroid carcinoma-associated hypercalcemia |
| Market Penetration |
High in North America (~85%) due to established guidelines, moderate in Europe, emerging in Asia |
Market Drivers
- Increasing prevalence of CKD affecting ~700 million globally (WHO, 2021)
- Rising incidences of secondary hyperparathyroidism linked to CKD progression
- Growing acceptance of calcimimetics as first-line adjunct therapy
- Expanding use in parathyroid carcinoma cases, although rare
- Improved formulations improving patient adherence and safety
Market Restraints
- High treatment costs (~USD 20,000 annually per patient)
- Safety concerns related to hypocalcemia
- Competition from newer calcimimetic agents and vitamin D analogs
- Limited reimbursement in certain markets
Competitive Landscape
| Company |
Product/Development |
Market Share (2022) |
Strengths |
Weaknesses |
| Amgen |
Sensipar (Cinacalcet) |
~88% |
Established, extensive clinical data |
Cost, adverse effects |
| Keryx (Auryxia) |
Ferric citrate (adjunct treatment) |
N/A |
Integrated approach |
Different mechanism |
| Reata Pharmaceuticals |
Experimental calcimimetic agents |
N/A |
Innovation |
Early-stage, regulatory hurdles |
Regulatory Environment
- FDA: Approved in 2004 for secondary hyperparathyroidism, latest approval for pediatric formulations in 2022.
- EMA: Approved in Europe since 2005, with ongoing assessments for expanding indications.
- Global Markets: Japan and China have approved generic versions, with local regulatory pathways under evaluation.
Market Projection
Forecast Assumptions
- Compound annual growth rate (CAGR): 4.1% (2023–2030)
- Increasing CKD prevalence and early intervention adoption
- Patent expiry and generic entry expected post-2028
- Continued clinical trials supporting expanded indications and formulations
- Regulatory approvals for novel combinations and formulations in emerging markets
Projected Market Size (2023–2030)
| Year |
Estimated Global Market (USD billion) |
Key Growth Factors |
| 2023 |
0.41 |
Steady demand; ongoing trials for new indications |
| 2025 |
0.48 |
Broadened indications; increased adoption in Asia |
| 2027 |
0.56 |
Entry of generics; price competition begins |
| 2029 |
0.65 |
Enhanced formulations, expanded pediatric use |
| 2030 |
0.72 |
Maturation of global markets, increased CKD burden |
Note: The projections rely on current trends; unforeseen regulatory or clinical developments may alter trajectory.
Comparison with Similar Drugs
| Drug |
Mechanism |
Indications |
Market Share (2022) |
Key Features |
Developmental Pipeline |
| Cinacalcet |
Calcimimetic |
SHPT, parathyroid carcinoma |
88% |
Oral, well-established |
Pediatric formulations, new combos |
| Etelcalcetide (Parsabiv) |
Calcimimetic (IV) |
SHPT in dialysis |
8% |
Parenteral |
Growing in US, Asia |
| Evocalcet |
Calcimimetic |
SHPT |
4% |
Fewer GI side effects |
Approved in Japan |
Deep Dive: Future Opportunities and Challenges
Opportunities
- Expanded indications: CKD stages 3 and 4, parathyroid carcinoma, and hypercalcemia due to malignancies.
- New formulations: Liquid, transdermal, and combination therapies.
- Personalized medicine: Biomarker-guided therapy to improve efficacy and safety.
- Market expansion: Emerging economies’ healthcare system developments.
Challenges
- Safety concerns: Managing hypocalcemia risks with broader use.
- Price sensitivity: Cost barriers in low-to-middle income regions.
- Competitive pressure: Innovating to stay ahead of generics and pipeline drugs.
- Regulatory hurdles: Approvals for new indications and formulations.
Key Takeaways
- Clinical pipeline development is robust, with trials targeting earlier-stage CKD and pediatric populations.
- Market remains mature in North America and Europe, but expansion opportunities exist, particularly in Asia and Latin America.
- Pricing and safety management are critical for sustaining market share amid generics and new entrants.
- Regulatory approvals of new formulations and indications could significantly boost market size through 2030.
- Long-term sustainability depends on innovation, cost management, and addressing unmet needs in CKD and parathyroid disorders.
FAQs
1. What are the primary clinical uses of Cinacalcet Hydrochloride?
Treats secondary hyperparathyroidism in CKD patients on dialysis, and hypercalcemia in parathyroid carcinoma.
2. Are there ongoing trials for new indications?
Yes. Recent trials are exploring use in CKD stages 3/4, pediatric populations, and combination therapies.
3. What are the main competitors to Cinacalcet?
Primarily etelcalcetide (Parsabiv), with newer calcimimetics and vitamin D analogs in development.
4. How will patent expirations influence the market?
Post-2028, generic versions are expected to enter, likely reducing prices and impacting revenue.
5. What regulatory advancements are anticipated?
Expanded approvals for pediatric formulations, new indications, and alternative delivery methods are projected.
References
[1] World Health Organization. "Global CKD Prevalence Data," 2021.
[2] U.S. Food and Drug Administration. "FDA Approvals for Cinacalcet," 2022.
[3] Amgen Inc. "Annual Clinical Data Reports," 2021–2022.
[4] Market Research Future. "Calcimimetic Drugs Market Analysis," 2022.
[5] ClinicalTrials.gov. "Ongoing Trials for Cinacalcet," 2023.
